Key facts
Lantern Pharma Inc.
New Form D on file · 2026-05-21 · the record
What the record says
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week.
Company officers on record
On the filing as: Executive Officer, Director.
Panna Sharma is named as Chief Executive Officer, President on the Form D that Lantern Pharma Inc. filed with the SEC on 21 May 2026, one of 8 people that filing names.
On the filing as: Director.
Donald Keyser is named as Chairman of the Board on the Form D that Lantern Pharma Inc. filed with the SEC on 21 May 2026, one of 8 people that filing names.
On the filing as: Executive Officer.
David Margrave is named as Chief Financial Officer, Secretary on the Form D that Lantern Pharma Inc. filed with the SEC on 21 May 2026, one of 8 people that filing names.
On the filing as: Executive Officer.
Kishor Bhatia is named as Chief Scientific Officer on the Form D that Lantern Pharma Inc. filed with the SEC on 21 May 2026, one of 8 people that filing names.
Vijay Chandru is named as Director on the Form D that Lantern Pharma Inc. filed with the SEC on 21 May 2026, one of 8 people that filing names.
Maria Maccecchini is named as Director on the Form D that Lantern Pharma Inc. filed with the SEC on 21 May 2026, one of 8 people that filing names.
Lee Schalop is named as Director on the Form D that Lantern Pharma Inc. filed with the SEC on 21 May 2026, one of 8 people that filing names.
David Silberstein is named as Director on the Form D that Lantern Pharma Inc. filed with the SEC on 21 May 2026, one of 8 people that filing names.
8 people named on the filing — 3 holding an executive role and 5 as directors only.
Named as of the 2026-05-21 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
- 8 people named on the filing — 3 holding an executive role and 5 as directors only.
No investor is drawn from a Form D — the form states how many invested and never who.
Want the whole picture on Lantern Pharma Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Lantern Pharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lantern Pharma Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Lantern Pharma Inc.
- Source Check — verify David R. Margrave's other claims against the registers that hold them.
- INVEST — size up this raise on the figures the filing states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with David R. Margrave for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Lantern Pharma Inc.You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Lantern Pharma Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. FoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.